Vilazodone Hydrochloride Tablet, Film Coated
Product Images NDC 0480-2043

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Vilazodone Hydrochloride (NDC 0480-2043). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Image 1)

Chemical structure of Vilazodone Hydrochloride, showing its molecular framework with distinct rings and functional groups, including the hydrochloride component.*

FDA Label Image

Fig1 (Image 2)

A pharmacokinetic (PK) fold change graph showing Cmax and AUC changes with 90% confidence intervals for Vilazodone Hydrochloride when coadministered with ethanol, CYP3A4 inhibitors (ketoconazole), CYP3A4 inducers (carbamazepine), and proton pump inhibitors (pantoprazole). The x-axis represents change relative to reference from 0.5 to 2.0, with markers indicating increases or decreases in PK parameters for each condition.*

FDA Label Image

Fig2 (Image 3)

A forest plot chart showing the fold change and 90% confidence intervals of pharmacokinetic parameters for various CYP enzyme and P-gp substrates relative to a reference. Substrates listed include nifedipine (CYP3A4), caffeine (CYP1A2), debrisoquine (CYP2D6), flurbiprofen (CYP2C9), mephenytoin (CYP2C19), and digoxin (P-gp), with changes displayed on an x-axis from 0.5 to 2.0 fold change.*

FDA Label Image

Fig3 (Image 4)

A forest plot showing pharmacokinetic fold changes and 90% confidence intervals for Vilazodone Hydrochloride in various population subgroups. It compares Cmax and AUC for age over 65, gender (females), renal impairment (mild, moderate, severe), and hepatic impairment (mild, moderate, severe) relative to a reference group.*

FDA Label Image

10mg (Image 5)

Label for Vilazodone Hydrochloride Tablets 10 mg, oral film-coated tablets. The package contains 30 tablets and is labeled for prescription use only. The label includes instructions for pharmacists to dispense the Medication Guide and identifies Teva Pharmaceuticals, Inc. as the labeler. The NDC is 0480-2045-56.*

FDA Label Image

1 (Image 6)

Label for Vilazodone Hydrochloride Tablets 20 mg, film-coated, oral dosage form from Teva Pharmaceuticals, Inc. The label includes the NDC 0480-2044-56, instructions for pharmacists to dispense a Medication Guide, and indicates a package size of 30 tablets. Additional regulatory and serialization information is present.*

FDA Label Image

40mg (Image 7)

Label for Vilazodone Hydrochloride Tablets 40 mg by Teva Pharmaceuticals, Inc. The film-coated oral tablets come in a package of 30 tablets. The label includes NDC 0480-2043-56, prescribing, dispensing instructions, safety warnings, and a serialization coding area. Teva logo appears on the bottom right.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.